Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473368 · ClinicalTrials.gov registry record · NA
Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT01473368: Completed NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT01473368 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01473368, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to compare and contrast the effects of the probiotic Saccharomyces boulardii, the antibiotic amoxicillin/clavulanate and the combination on the gut microbiota of healthy volunteers.
Primary Outcome
Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms
Interventions
- DIETARY_SUPPLEMENT Saccharomyces boulardii
- DRUG Amoxicillin Clavulanate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-02 |
| Phase | NA |
What the finished NCT01473368 record still lists
NCT01473368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Saccharomyces boulardii is the first listed.
NCT01473368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01473368 about?
NCT01473368 is a clinical study titled "Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota". The purpose of this study is to compare and contrast the effects of the probiotic Saccharomyces boulardii, the antibiotic amoxicillin/clavulanate and the combination on the gut microbiota of healthy volunteers.
What is the current status of trial NCT01473368?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2012-04. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01473368?
The interventions under investigation include: Saccharomyces boulardii (DIETARY_SUPPLEMENT), Amoxicillin Clavulanate (DRUG).
Who is sponsoring clinical trial NCT01473368?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01473368's enrollment target sits among peer trials
53 1271st of 2000 higher than 729 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia